Neogen Chemicals: Business Overview & Financial Analysis
Neogen Chemicals is a prominent Indian specialty chemicals manufacturing enterprise headquartered in Thane, Maharashtra. Promoted by Haridas Kanani and Dr. Harin Kanani, the company manufactures bromine-based and lithium-based specialty chemicals, advanced intermediates, and custom synthesis solutions. Operating manufacturing facilities across Mahape (Navi Mumbai), Karakhadi (Vadodara, Gujarat), and Dahej SEZ (Gujarat), Neogen Chemicals serves pharmaceutical, agrochemical, engineering, and battery energy storage sectors across 30+ countries globally.
Segment Revenue Mix of Neogen Chemicals (Q1 FY2027)
Neogen Chemicals structures its operational turnover across core Organic Chemicals (Bromine & Advanced Intermediates) and Inorganic Chemicals (Lithium Salts) divisions.
- Organic Chemicals Share – 74.5% of Operating Revenue (Rs 148.20 crore)
- Inorganic Chemicals Share – 25.5% of Operating Revenue (Rs 50.80 crore)
- Total Consolidated Revenue from Operations (Q1 FY2027) – Rs 199.00 crore (+9.8% YoY)
Organic chemicals generate nearly three-fourths of corporate turnover, driven by bromine derivatives and complex pharma/agrochemical intermediates. The inorganic chemicals vertical supplies lithium salts for HVAC absorption chillers and battery technology applications.
Product Portfolio & Technical Capabilities of Neogen Chemicals (FY2026)
The company manages a product catalog spanning bromine compounds, organo-lithium complexes, and specialty battery electrolyte salts.
- Product Catalog Scale – 240+ specialty chemical and advanced intermediate products
- Core Chemistry Competencies – Bromination, Grignard reaction, Alkylation, Sestriction, and Lithium Chemistry
- Battery Materials Expansion – Electrolytes and lithium salts (LiPF6) for EV lithium-ion batteries
- Global Technology Licensing – Technology transfer partnership with MU Ionic Solutions (MUIS), Japan, for electrolyte manufacturing
Managing 240+ specialty chemical products supports long-term customer relationships with generic pharma and agrochemical majors. Partnering with Japan's MU Ionic Solutions (Mitsubishi Chemical Group unit) enables technology transfer to manufacture EV battery electrolytes in India.
Manufacturing Infrastructure & Facilities Scale of Neogen Chemicals (Q1 FY2027)
Neogen Chemicals operates multi-purpose reaction blocks and glass-lined reactors across three key manufacturing complexes in Maharashtra and Gujarat.
- Total Operating Manufacturing Facilities Base – 3 manufacturing complexes in Mahape, Karakhadi, and Dahej SEZ
- Total Organic Chemical Reaction Capacity – ~430,000 Litres (430 KL) operational reactor capacity
- Total Inorganic Chemical Manufacturing Scale – 39,000 Metric Tonnes per annum (MTPA)
- Greenfield Electrolyte Plant Project – 30,000 MTPA electrolyte plant development under subsidiary Neogen Ionics at Pakhajan, Gujarat
Operating 430 KL of organic reactor volume supports multi-stage custom synthesis for global innovator clients. Developing a 30,000 MTPA electrolyte plant in Pakhajan establishes Neogen Chemicals as an early-mover in India's electric vehicle supply chain.
Geographic Revenue Mix & Export Distribution of Neogen Chemicals (Q1 FY2027)
The enterprise balances its product dispatches between domestic Indian industrial consumers and international export destinations.
- Domestic Indian Market Share – 58.0% of Total Operating Revenue (Rs 115.42 crore)
- International Export Market Share – 42.0% of Total Operating Revenue (Rs 83.58 crore)
- Overseas Export Footprint Reach – Sales dispatches across 30+ countries in Europe, USA, Japan, and Middle East
Domestic sales generate nearly six-tenths of total business turnover, driven by pharmaceutical and agrochemical synthesis demand. Export dispatches to Japan, Europe, and the US support international sales growth.
Latest Quarterly Financial Performance of Neogen Chemicals (Q1 FY2027)
Neogen Chemicals recorded top-line revenue expansion alongside operating margin improvement during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 199.00 crore (+9.8% YoY vs Rs 181.30 crore in Q1 FY2026)
- Consolidated Operating EBITDA – Rs 32.80 crore (+14.3% YoY vs Rs 28.70 crore in Q1 FY2026)
- Consolidated Operating EBITDA Margin – 16.48% (+65 bps YoY vs 15.83%)
- Consolidated Net Profit After Tax (PAT) – Rs 11.20 crore (+15.5% YoY vs Rs 9.70 crore in Q1 FY2026)
- Standalone Net Profit After Tax (PAT) – Rs 10.80 crore
First-quarter consolidated operating revenue expanded 9.8% year-on-year to Rs 199.00 crore, supported by volume recovery in organic intermediates. Consolidated Net Profit After Tax reached Rs 11.20 crore, while operating EBITDA margins expanded to 16.48%.
Consolidated Annual Financial Performance of Neogen Chemicals (FY2026)
The company achieved full-year turnover growth and cash flow conversion during full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 740.50 crore (+7.2% YoY)
- Full Year Consolidated Operating EBITDA – Rs 120.40 crore (+8.5% YoY)
- Full Year Operating EBITDA Margin – 16.26% (+20 bps YoY)
- Full Year Consolidated Net Profit After Tax (PAT) – Rs 38.50 crore (+10.2% YoY)
- Return on Capital Employed (ROCE) Realisation – ~11.5%
- Return on Equity (ROE) Realisation – ~8.8%
Full-year operating turnover crossed Rs 740.00 crore in FY2026, as consolidated Net Profit After Tax reached Rs 38.50 crore. Delivering an operating EBITDA margin of 16.26% reflects product pricing pass-through mechanisms on raw lithium and bromine inputs.
Balance Sheet Structure & Financial Health Ratios of Neogen Chemicals (Q1 FY2027)
Neogen Chemicals operates a capital structure backed by equity net worth, project term loans, and working capital lines.
- Consolidated Net Debt to Equity Ratio – 0.65x (Elevated due to electrolyte capex outlays)
- Total Consolidated Shareholder Equity Net Worth Base – ~Rs 710.00 crore
- Working Capital Conversion Cycle – 115 days (Driven by lithium raw material inventory holdings)
- Credit Rating Profile – Reaffirmed '[CRISIL] A (Stable)' / 'CARE A (Stable)'
Operating a net debt-to-equity ratio of 0.65x reflects ongoing capital deployment into greenfield battery material projects. Reaffirming long-term credit ratings at '[CRISIL] A (Stable)' confirms balance sheet stability and project execution capability.
Capex Allocation & Battery Materials Project Roadmap of Neogen Chemicals (FY2027–FY2028)
The enterprise executes a structured capital expenditure plan to construct its greenfield electrolyte plant, expand Dahej organic capacity, and scale lithium salts.
- Greenfield Electrolyte Capex Outlay (Neogen Ionics) – Rs 450.00+ crore multi-year capex for 30,000 MTPA electrolyte & 5,500 MTPA electrolyte salts
- Dahej Organic Capacity Debottlenecking Outlay – Rs 40.00 crore to add 60 KL reactor capacity
- Electrolyte Plant Commercialization Schedule – Phase 1 commercial production targeted for commissioning in FY2028
- Planned Annual Group Capex Guidance – Rs 150.00 to Rs 200.00 crore per annum
- Funding Strategy – Funded through debt financing, internal cash accruals, and preferred equity infusions
Capital expenditure outlays focus on commercializing Phase 1 of the Pakhajan electrolyte facility in Gujarat. Expanding reactor capacity at Dahej by 60 KL supports custom synthesis contracts for agrochemical clients.
Strategic Outlook & Management Commentary of Neogen Chemicals (Q1 FY2027 Concall)
Management guidance outlines strategic priorities centered on custom synthesis scaling, electrolyte project commissioning, and margin recovery.
- Management targets achieving consolidated revenues between Rs 1,000.00 and Rs 1,200.00 crore once electrolyte facilities scale.
- Consolidated operating EBITDA margins are guided to sustain between the 16.5% and 17.5% corridor.
- Advanced intermediates and CSM (Custom Synthesis Manufacturing) revenue contribution share is targeted to scale past 35%.
- Electrolyte customer qualification trials with major Indian EV cell manufacturers are progressing on schedule.
- Bromine raw material prices have stabilized, supporting margin recovery in organic chemical synthesis.
- Capital allocation strategy will prioritize self-funded CSM expansions while managing leverage during electrolyte construction.
Management anticipates strong demand for custom synthesis and lithium-ion battery materials to drive long-term business growth. Operational focus centers on executing the Pakhajan electrolyte project, securing commercial supply contracts with battery cell makers, and preserving balance sheet health.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Neogen Chemicals Q1 FY2027 Financial Disclosures & Press Release (August 2026)
- Neogen Chemicals Stock Exchange Outcomes & Corporate Filings
- Investor Presentation & Performance Updates for Neogen Chemicals
- Board Meeting Results & Regulatory Filings for Neogen Chemicals
- Ticker Finology Neogen Chemicals Page
Disclaimer
The information presented above on Neogen Chemicals has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Neogen Chemicals page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.